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Abstract 
The lucrative market of herbal remedies spurs rampant adulteration, particularly with 
pharmaceutical drugs and their unapproved analogues. A comprehensive screening 
strategy is, therefore, warranted to detect these adulterants, and accordingly, to 
safeguard public health. This study utilises the data-dependent acquisition of a liquid 
chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) to 
screen phosphodiesterase 5 (PDE5) inhibitors in herbal remedies using suspected-
target and non-targeted strategies. The suspected-target screening employed a library 
comprising 95 PDE5 inhibitors. The non-targeted screening adopted top-down and 
bottom-up approaches to flag novel PDE5 inhibitors analogues based on common 
fragmentation patterns. The LC-QTOF-MS was optimised and validated for capsule 
and tablet dosage forms using 23 target analytes, selected to represent different 
groups of PDE5 inhibitors. The method exhibited excellent specificity and linearity with 
limit of detection and limit of quantification of <40 ng/mL and 80 ng/mL, respectively. 
The accuracy ranged from 79.0%–124.7% with precision of <14.9%RSD. The 
modified QuEChERS extraction provided insignificant matrix effect within -9.1%–8.0% 
and satisfactory extraction recovery of 71.5%–105.8%. These strategies were utilised 
to screen 52 herbal remedy samples that claimed to enhance male sexual 
performance. The suspected-target screening resulted in 33 positive samples, 
revealing ten target analytes and two suspected analytes. Systematic MS and tandem 
MS interrogations using the non-targeted screening returned insignificant signals, 
indicating the absence of potentially novel analogues. The target analytes were 
quantified from 0.03–121.31 mg per dose of each sample. The proposed strategies 
ensure all PDE5 inhibitors are comprehensively screened, providing a useful tool to 
curb the widespread adulteration of herbal remedies. 
 
 
This article is protected by copyright. All rights reserved. 
Keywords: LC-QTOF-MS, suspected-target screening, non-targeted screening, 
herbal remedies, PDE5 inhibitors 
 
1. INTRODUCTION 
Globally, people consume an array of health products to treat minor ailments, prevent 
illnesses, and boost their health and well-being1. Herbal remedies have recently 
surged to be a substantial part of this market due to the many side effects associated 
with modern medicines. At present, the herbal industry is one of the most rapidly 
growing sectors with annual sales over several billion dollars worldwide2. Herbal 
remedies are typically marketed in pharmaceutical dosage forms and apportioned into 
specific doses. 
 
Herbal remedies commonly claim to be of natural origin, giving the perception of being 
effective and safe3. However, this lucrative market often tempts intentional adulteration 
with pharmaceutical drugs and their unapproved analogues, aimed to provide the 
desired efficacy which may pose severe health and life-threatening risks to 
consumers2,4. Among the most prevalent include products adulterated with 
phosphodiesterase 5 (PDE5) inhibitors and their analogues, frequently marketed to 
enhance male sexual performance5. 
 
Novel PDE5 inhibitors analogues used as adulterants pose a challenge to forensic 
drug testing laboratories, as they may evade detection during routine screening6. As 
a result, the adulterated herbal remedies may be distributed in the market undetected, 
putting the consumers at absolute risk, owing to the unknown safety and toxicology 
profiles7. Thus far, the literature has identified more than 90 unapproved PDE5 
 
 
This article is protected by copyright. All rights reserved. 
inhibitors analogues as adulterants8. From 2015 to 2019, the United States Food and 
Drug Administration (USFDA) had reported that 260 out of 390 adulterated products 
contain PDE5 inhibitors and their analogues9. 
 
The literature described several analytical methods to determine PDE5 inhibitors in 
various matrices, for instance, thin layer chromatography (TLC)10, gas 
chromatography-mass spectrometry (GC-MS)11, Raman spectroscopy12, and nuclear 
magnetic resonance (NMR) spectroscopy13. More frequently, liquid chromatography 
(LC) coupled with mass spectrometry (MS) detection in tandem mode has 
demonstrated to be an indispensable tool in the analysis of PDE5 inhibitors. The 
analyses used both low-resolution MS14 and high-resolution MS (HRMS)8. However, 
HRMS has proven to be superior as it delivers full-spectral information for both MS 
and tandem MS mode simultaneously15, which provides an unrivalled specificity. 
 
In recent years, researchers are getting more interested in HRMS techniques such as 
quadrupole time-of-flight MS (QTOF-MS), as they can use the full-spectral information 
to develop targeted, suspected-target, and non-targeted analysis15,16.  However, the 
widely used targeted analysis is limited, depending on the availability of certified 
reference materials (CRMs)17. In the case of PDE5 inhibitors identification, it would 
not be financially viable for forensic drug testing laboratories to acquire all the available 
CRMs. Therefore, suspected-target screening provides extended coverage of known 
analytes without the need for CRMs. Additionally, non-targeted screening can address 
the growing concerns of the novel PDE5 inhibitors analogues found as adulterants. 
This strategy plays a pivotal role to discover those novel analogues based on the 
common fragmentation patterns of the known PDE5 inhibitors. 
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This study utilised the data-dependent acquisition (DDA) of an LC-QTOF-MS for 
comprehensive screening of PDE5 inhibitors and their analogues in herbal remedies. 
The screening procedure was carefully developed using suspected-target and non-
targeted strategies. The analytical method was optimised and validated using 23 target 
analytes, ensuring robust and reliable performance to determine PDE5 inhibitors in 
different herbal remedies’ matrices. These strategies were then employed to screen 
52 distinct samples of herbal remedies that claimed to enhance male sexual 
performance. The highlighted significant results showcased the applicability of the 
developed screening strategies. 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents 
In total, the 23 CRMs of PDE5 inhibitors purchased from TLC Pharmaceutical 
Standards Ltd (Aurora, Ontario, Canada) were as follows: (1) desmethylcarbodenafil, 
(2) carbodenafil, (3) N-desethylacetildenafil, (4) acetildenafil, (5) hydroxyvardenafil, (6) 
dimethylacetildenafil, (7) vardenafil, (8) sildenafil, (9) homosildenafil, (10) 
dimethylsildenafil, (11) propoxyphenyl-hydroxyhomosildenafil, (12) udenafil, (13) 
propoxyphenyl-sildenafil, (14) hydroxythiovardenafil, (15) tadalafil, (16) mirodenafil, 
(17) mutaprodenafil, (18) thiosildenafil, (19) thiohomosildenafil, (20) 
dithiodesmethylcarbodenafil, (21) thiodimethylsildenafil, (22) propoxyphenyl-
thiohydroxyhomosildenafil, and (23) propoxyphenyl-thiodimethylsildenafil. Each of the 
CRM was carefully selected as target analytes to represent different groups of PDE5 
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The vendor for methanol and acetonitrile of LC-MS grade was Chem-Supply Pty Ltd 
(Gillman, SA, Australia); while Sigma Aldrich Pty Ltd (Castle Hill, NSW, Australia) 
supplied the formic acid of LC-MS grade and ammonium formate of analytical grade. 
Ultrapure water (18.2 MΩ-cm) was collected from a Sartorius arium® pro ultrapure 
water system (Goettingen, Germany); and LECO Australia Pty Ltd (Castle Hill, NSW, 
Australia) supplied the quick, easy, cheap, effective, rugged, and safe (QuEChERS) 
extraction salt (EN 15662). Each sachet of the QuEChERS extraction salt is composed 
of 4 g magnesium sulphate, 1 g sodium chloride, 1 g trisodium citrate dihydrate, and 
0.5 g disodium hydrogen citrate sesquihydrate. 
 
2.2. Standard solution preparation 
The stock solution of each CRM was prepared in methanol at 1 mg/mL and stored in 
the dark at 4°C. A mixture of all CRMs (working solution) was freshly prepared for 
each analysis from the stock solutions by further dilution in methanol to make up to 25 
µg/mL concentration. 
 
2.3. Sample collection and storage 
Altogether, the 52 distinct herbal remedy samples in capsule and tablet dosage forms 
were obtained from Malaysia (44 samples) and Australia (8 samples). These 
suspected samples were selected based on brand names, label claims, images, 
herbal ingredients, or advertising materials related to male sexual performance. The 
Pharmacy Enforcement Division, Ministry of Health Malaysia, kindly donated most of 
these samples which were confiscated at the international airport (10 samples) and 
international seaport (16 samples), including those from routine market surveillance 
activities (17 samples). The remainder of the samples were purchased from various 
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online shopping platforms based in Malaysia (1 sample) and Australia (8 samples).  
Each sample was labelled as SPC001 to SPC032 for capsule samples and SPT001 
to SPT020 for tablet samples. These samples were deposited in a plastic zip-lock bag 
individually and then stored in an airtight container in the dark.  
 
A representative blank matrix of capsule or tablet, free from any analyte of interests, 
was sourced from a local pharmacy in Australia and used for method optimisation and 
validation. The compositions of the capsule utilised as a blank matrix were as follows: 
Epimedium sagittatum, Eleutherococcus senticosus, Tribulus terrestris, Dulacia 
inopiflora, zinc oxide, and encapsulating aids. Meanwhile, the tablet employed as a 
blank matrix was composed of Morinda officinalis, Epimedium sagittatum, Panax 
ginseng, Schisandra chinensis, Serenoa repens, lycopene, zinc amino acid chelates, 
calcium hydrogen phosphate, carnauba wax, microcrystalline cellulose, chlorophyllin-
copper complex, croscarmellose sodium, magnesium stearate, silica, and tablet 
coating ingredients. The constituents of these two blank matrices were stated on the 
products’ labels. 
 
2.4. Sample preparation 
The initial weight of each sample was recorded according to the recommended dose 
on its label. Then, using an electric grinder for capsules or a mortar and pestle for 
tablets, the entire recommended dosage was homogenised. For instrumental analysis, 
100 mg of the homogenised sample was weighed in a polypropylene tube and then 
extracted with 5 mL of acetonitrile and methanol (1:1, v/v) by 1-min vortex mixing, 20-
min sonication, and 5-min centrifugation at 2500 × g, successively. The resulting 
mixture was then transferred into another polypropylene tube prefilled with half of a 
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sachet of the QuEChERS extraction salt (2 g magnesium sulphate, 0.5 g sodium 
chloride, 0.5 g trisodium citrate dihydrate, and 0.25 g disodium hydrogen citrate 
sesquihydrate); and vortexed for 1 min, followed by centrifugation for 5 min at 2500 × 
g to separate the solid residues. The upper layer was filtered using a 0.22 µm PTFE 
syringe filter and diluted with methanol at 1:10 dilution level for analysis. The blank 
matrices were treated in the same manner as the sample analysis. For quantification 
purpose, the sample solution was further diluted with methanol whenever the target 
analyte concentration was beyond the linear range of the external calibration curve. 
 
2.5. LC-QTOF-MS conditions and data analysis 
This study employed an Agilent Technologies (Santa Clara, CA, USA) 1290 Infinity II 
LC system coupled to an Agilent Technologies 6510 QTOF-MS using our previously 
developed methodology8,18. The chromatographic separation was carried out using a 
reverse-phase high-performance LC column from Merck KGaA (Darmstadt, Germany) 
Chromolith® High-Resolution RP-18 end-capped (100 × 4.6 mm, 2.0 µm) with column 
compartment temperature maintained at 20°C. 
 
The injection volume was set at 5 µL with the autosampler compartment temperature 
maintained at 10°C. The mobile phases were acidified with 0.1% v/v formic acid and 
consisted of solvent A (10 mM ammonium formate in ultrapure water) and solvent B 
(acetonitrile). The settings of the gradient elution were as follows: 5% B for 0–1 min, 
5%–25% B for 1–2 min, 25%–50% B for 2–32 min, 50%–95% B for 32–33 min, and 
95% B for 33–34 min at 0.4 mL/min. The elution was immediately returned to the initial 
gradient at 34.01 min for 6 min at 1 mL/min. Post-run equilibration was set for 5 min 
at 0.4 mL/min before the next injection. 
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The QTOF-MS, equipped with a dual electrospray ionisation (ESI) nebuliser was 
calibrated at a low mass range of m/z 1700 before each chromatographic run to 
achieve a typically attainable mass accuracy within ±5 ppm for precursor ion and ±20 
ppm for product ion. ESI in positive ionisation mode was employed using the following 
experimental parameters: 300°C for gas temperature, 12 L/min for drying gas flow, 32 
psig for nebuliser pressure, 3500 V for capillary voltage, 175 V for fragmentor voltage, 
65 V for skimmer voltage, and 750 V for OCT 1 RF Vpp. 
 
A DDA (auto MS/MS) mode was selected for simultaneous MS and tandem MS 
experiments within a mass-to-charge range of m/z 100 to 1100. The acquisition rates’ 
settings were 1 and 3 spectra/s for the MS and tandem MS experiments, respectively, 
within a narrow isolation width of m/z ~1.3. The collision-induced dissociation 
experiments were performed at fixed collision energies (CEs) of 10, 20, and 40 eV in 
a separate scan with nitrogen as the collision gas. The reference mass solution 
containing purine (m/z 121.050873) and hexakis (1H, 1H, 3H-tetrafluoropropoxy) 
phosphazine (m/z 922.009798) were continuously infused throughout the 
chromatographic run at a steady pressure of 5 psig. 
 
Agilent Technologies Mass Hunter workstation software version B.07.00, Mass Hunter 
qualitative analysis software version B.07.00, and personal compound database and 
library (PCDL) manager software version B.04.00 were used to process all qualitative 
and quantitative data. All other calculations were done using Microsoft (Redmond, WA, 
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2.6. Analytical method validation  
The analytical method validation was performed for specificity, linearity, limit of 
detection (LOD), and limit of quantification (LOQ)19. The accuracy, precision, matrix 
effect (ME), and extraction recovery (RE) were also evaluated for each target analyte 
in each of the blank matrices of capsule and tablet at low (0.1 µg/mL), medium (0.4 
µg/mL), and high (1 µg/mL) quality control (QC) levels following the recommended 
procedures20. All validation parameters were analysed in triplicate. 
 
Each target analyte was evaluated for specificity based on (1) the chromatographic 
separation and (2) the high-resolution mass of the protonated molecule ([M+H]+). The 
tandem MS experiment was then used to establish the presence of two product ions 
corresponding to each target analyte. The average intensity ratio between the first and 
the second product ion at average CEs was compared to those obtained from the 
matrix-matched QC analytes within ±30% and thus, confirming the target analytes’ 
identity. The extent of interfering components from the extracted blank matrices was 
also ascertained at the retention time of each target analytes. 
 
An external calibration curve was constructed using the peak areas of each target 
analyte from the [M+H]+ precursor ion versus their concentrations. The linearity was 
then determined based on the coefficient of determination (r2), and the regression 
equation was used to calculate the QC analytes and samples concentrations. The 
lowest and highest concentrations of target analytes expected in adulterated herbal 
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The LOD was determined experimentally by tapering down each point of 10 ng/mL of 
the working solution concentration starting from 100 to 10 ng/mL. The LOD was then 
selected based on the lowest concentration of target analyte that can be reliably 
identified as defined in the specificity assessment. The LOQ was established at the 
lowest concentration of the external calibration curve with acceptable accuracy and 
precision. Whenever a background noise is present, the signal-to-noise ratio was 
ascertained at >3 for LOD and >10 for LOQ. 
 
The accuracy and precision were established at three QC levels. The extracted blank 
matrices were spiked with the working solution and submitted to analysis. The 
observed target analyte concentration versus the expected concentration at the same 
QC level was expressed as a percentage of accuracy with an acceptable value of 
±25%. Precision was determined using the same QC analytes at intra-day for 
repeatability and inter-day for intermediate precision. The results were then expressed 
as a percentage of the relative standard deviation (%RSD) of the peak areas of the 
[M+H]+ precursor ion with an acceptable value of <20%. 
 
Using the same QC levels, the ME was evaluated based on the post-extraction 
addition method8. The slopes of the matrix-matched calibration curve versus those of 
the external calibration curve were compared to determine the percentage of ionisation 
suppression (negative value) or ionisation enhancement (positive value). The ME 
categories for each target analyte in both matrices were as follows: insignificant (0% 
to ±10%), acceptable (±10% to ±20%), moderate (±20% to ±50%), and severe (-50%< 
>+50%). In contrast, the comparison of the peak areas of the [M+H]+ precursor ion of 
target analytes spiked into the blank matrices before extraction versus those spiked 
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into an extracted blank matrix at the same QC level, generated the percentage of RE 
with an acceptable value of ±25%.  
 
2.7 Suspected-target and non-targeted screenings of herbal remedies 
The screening of PDE5 inhibitors and their analogues as adulterants in herbal 
remedies was performed using suspected-target and non-targeted strategies. For the 
suspected-target screening, a library was constructed using the PCDL manager 
software. The library comprised of 95 PDE5 inhibitors and their analogues that are 
presently known as adulterants (listed in Table S7 of the supplementary data). Specific 
details such as compound name, molecular formula and structure, and exact mass 
were manually stored in this library. Also, extended details from the LC-QTOF-MS 
analysis of the 23 target analytes were imported from the Mass Hunter qualitative 
analysis software into the same library, which includes the retention time and tandem 
MS spectra at different CEs. 
 
The suspected-target screening was employed to match the observed accurate mass 
of the [M+H]+ precursor ion of the sample to those theoretical ones in the library within 
±5 ppm mass tolerance. The matching scores of the observed mass, isotopic 
abundance distribution, and isotopic spacing for each analyte were also ascertained 
to be >80%. Based on these findings, a list of matched analytes was generated. Next, 
the observed tandem MS spectra of the sample were compared to those of target 
analytes within ±20 ppm mass tolerance. Subsequently, the identity of each target 
analyte was confirmed by comparing the observed retention time to those of the CRMs 
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At this stage, there are two possible outcomes for positive samples, where: (1) sample 
matched with target analytes and (2) sample matched with suspected analytes. Only 
samples in outcome number (1) were submitted to quantification. Whereas, a list of 
suspected analytes was generated for outcome number (2). The negative samples 
were tentatively categorised as possible non-adulterated samples and were submitted 
to the non-targeted screening. 
 
The non-targeted screening was performed using comprehensive top-down and 
bottom-up approaches to screen visible and non-visible chromatographic peak, 
respectively. The screening was adapted and modified following a critical review by 
Pasin et al.15 to flag novel PDE5 inhibitors analogues based on common fragmentation 
patterns of target analytes. The visible peaks within a base peak chromatogram (BPC) 
were integrated and extracted using the top-down approach to reveal the mass 
spectra. Each of this spectrum was then interrogated for the [M+H]+ precursor ions. 
Using the product ion scan of the Mass Hunter qualitative analysis software, the link 
between the pre-determined [M+H]+ precursor ions and the product ions of target 
analytes was established at the specific retention time of each chromatographic peak. 
 
In contrast, with the bottom-up approach, all generated [M+H]+ precursor ions during 
the chromatographic run were considered to establish if there is any link to the product 
ions of target analytes. Therefore, additional investigations are required to ultimately 
establish the correct [M+H]+ precursor-product ion pair. In both approaches, any two 
tandem MS signals observed belonging to the same group of PDE5 inhibitors within 
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3. RESULTS AND DISCUSSION 
3.1. Method optimisation 
The simultaneous separation of multiple PDE5 inhibitors with structural similarities is 
critical for a reliable determination of these adulterants, particularly from complex 
matrices such as herbal remedies. The mobile phases, matrix modifier, and 
chromatographic column were initially selected based on the physical and chemical 
properties of target analytes to obtain optimum chromatographic resolution. The 
chromatographic separation was then optimised by varying the LC parameters such 
as injection volume, flow rate, column temperature, elution gradient, and elution time. 
The MS conditions were tuned according to the flow- and compound-dependent 
parameters to improve the method sensitivity. The chromatographic separation and 
MS conditions were optimised following the previous literature18. 
 
Although the LC-QTOF-MS via ESI is superior in detecting analytes from complex 
matrices, its performance is often hindered by the presence of ME, which often lead 
to errors in quantification21. Therefore, the presence of either ionisation suppression 
or ionisation enhancement needs to be addressed to minimise the possibilities of false-
negative and false-positive results. Consequently, two extraction techniques were 
compared and assessed based on the ME and RE efficiency to resolve this issue. The 
ME was also evaluated at three levels of matrix dilution while maintaining the target 
analytes concentration at three QC levels. 
 
The widely used dilute-and-shoot (D&S) technique was initially performed to analyse 
the PDE5 inhibitors in the blank matrices. Methanol was chosen as the solvent for this 
technique based on previous literature22,23. The capsule matrix produced moderate 
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ME for two and acceptable ME for eight target analytes at 1:2 matrix dilution. The 
remaining 13 target analytes showed insignificant ME. However, non-detection of 
several target analytes at the same matrix dilution was observed for the tablet matrix 
at low and medium QC levels. Therefore, the ME cannot be determined for seven 
target analytes, particularly those with pyrazolopyrimidine-7-thione and 
imidazotriazine-4-thione moiety. The same problem persisted for the tablet matrix at a 
higher 1:10 matrix dilution. In general, the ME was minimised to insignificant 
percentages with increasing matrix dilution from 1:2 to 1:100 for all target analytes in 
both matrices. 
 
From the D&S ME assessment, the presence of the tablet matrix had resulted in a 
complete loss of MS signals which subsequently led to false-negative results of the 
seven target analytes. Consequently, another sample extraction technique was 
assessed to overcome this problem. After several trial-and-error, a modified 
QuEChERS procedure was developed specifically to resolve the ME issue. The 
application of the modified QuEChERS extraction in combination with appropriate 
matrix dilution had resulted in insignificant ME percentages for both matrices at 1:10 
and 1:100 matrix dilution. Finally, the 1:10 matrix dilution was selected and submitted 
to RE assessment. Table S8 (supplementary data) presents the full ME assessment 
results of the blank matrices using D&S technique and modified QuEChERS extraction 
at three levels of matrix dilution. 
 
3.2. Analytical method validation 
Table S9 (supplementary data) shows the specificity, linearity, and sensitivity results 
of the analytical method. The presence of each target analyte was ascertained using 
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the optimised chromatographic separation and the full-scan MS data of the [M+H]+ 
precursor ion. Isomeric analytes were chromatographically resolved, qualifying their 
specificity. Furthermore, the presence of two product ions from the tandem MS 
experiment confirmed the target analytes’ identities. The effects of interferences from 
the extracted blank matrices were established to be trivial. Moreover, the carry-over 
effect was not observed in the subsequent analysis using the optimised 
chromatographic separation as the reverse-phase high-performance LC column was 
flushed with approximately five times of the column volume starting from 34.01–40 min 
at 1 mL/min before the next sample injection. The linear relationship between the peak 
areas of target analytes and their concentrations was verified by r2 of >0.9870 within 
the selected range of 0.08–1.2 μg/mL. The LOD was determined between 10–40 
ng/mL, while the LOQ was fixed at 80 ng/mL for all target analytes. 
 
Supplementary Table S10 and S11 respectively, present the accuracy and precision 
data. Excellent accuracy was obtained for both capsule and tablet matrices. The 
capsule matrix produced the percentage of accuracy ranged from 90.8%–123.1% at 
low; 94.4%–104.9% at medium; and 95.6%–103.4% at high QC level. The percentage 
of accuracy for tablet matrix at low, medium, and high QC levels were within 79.0%–
124.7%; 93.8%–109.9%; and 90.8%–103.9%, respectively. The precision was also 
satisfactory with the %RSD of <14.9%. The repeatability and intermediate precision 
for both matrices were calculated within 0.3%–8.6% and 0.1%–14.9% of RSD, 
respectively, at all QC levels. 
 
As mentioned in Section 3.1, the ME was within insignificant percentages for all target 
analytes. The MEs for capsule and tablet matrices were within -9.1%–1.7% and -
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3.7%–8.0%, respectively. Table S12 (supplementary data) shows the RE results of 
the modified QuEChERS extraction. The RE was satisfactory within 72.6%–105.8% 
for capsule matrix and 71.5%–102.3% for tablet matrix. 
 
3.3 Screenings of herbal remedies for PDE5 inhibitors 
A total of 52 distinct herbal remedy samples obtained from Malaysia and Australia 
were comprehensively screened using suspected-target and non-targeted strategies. 
The top three countries of origin based on the products’ label are Malaysia, China 
(Hong Kong), and Indonesia. Most of these samples claimed to contain Eurycoma 
longifolia, Tribulus terrestris, and Panax ginseng, which are usually regarded as herbal 
aphrodisiacs. Table 1 compiles the analysis results of the adulterated herbal remedy 
samples.  
 
The suspected-target screening generated a list of 12 matched analytes from 33 
samples. The tandem MS and retention time matching subsequently confirmed the 
identity of each analyte, particularly distinguishing those with isomeric configurations. 
Based on these findings, ten target analytes were identified from 32 samples and 
quantified. Just two suspected analytes, i.e. aminotadalafil and 
hydroxythiohomosildenafil, were detected from 3 samples (2 samples contained a 
combination of target analytes and suspected analytes while another 1 sample 
contained only suspected analyte). The remaining 19 of possibly non-adulterated 
samples were submitted to the non-targeted screening. Systematic MS and tandem 
MS interrogations using top-down and bottom-up approaches returned insignificant 
signals, and no novel PDE5 inhibitors analogues were detected; thereby, confirming 
the negative results. 
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Fig. 1A summarises the identification of target analytes and the detection of suspected 
analytes in adulterated herbal remedy samples. The active ingredient of Viagra®: 
sildenafil, was identified in nearly half of the samples. It was found in 19 samples as a 
sole adulterant and 6 samples in combinations with other PDE5 inhibitors. Other target 
analytes identified in this study were as follows: propoxyphenyl-sildenafil, tadalafil, and 
thiodimethylsildenafil (4 samples each); dimethylsildenafil and thiosildenafil (3 
samples each); and propoxyphenyl-hydroxyhomosildenafil, propoxyphenyl-
thiodimethylsildenafil, propoxyphenyl-thiohydroxyhomosildenafil, and vardenafil (1 
sample each). These target analytes can either be present as a sole adulterant or in 
combinations of up to four different adulterants in any one sample.  
 
These findings indicated that sildenafil is the most prevalent adulterant detected 
among the 33 adulterated samples. Similarly, analogues of sildenafil are frequently 
detected compared to those of tadalafil and vardenafil. The trends may be attributed 
to the easily accessible and inexpensive cost of raw materials to obtain or synthesise 
the adulterants24. Furthermore, the synthesis steps are readily available from the 
patent literature, which could yield hundreds of active sildenafil analogues25. 
 
The total target analytes quantified for each recommended dose ranged from 0.03–
121.31 mg per sample. These findings were then categorised based on the 
recommended dose of the approved PDE5 inhibitors (i.e. 25–100 mg for sildenafil and 
5–20 mg for vardenafil and tadalafil)26, summarised in Fig. 1B. The quantification of 
target analytes was indicative of supratherapeutic level for 10 samples. Sildenafil (7 
samples) and tadalafil (2 samples), in particular, were quantified exceeding their 
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maximum therapeutic dose of 100 mg and 20 mg, respectively. Sample SPC027 
notably contains four distinct analogues of sildenafil, combined to produce a 
supratherapeutic level of PDE5 inhibitors. The high dose of these adulterants generally 
increases the incidence of side effects which could easily jeopardise consumers' 
health and well-being. In some cases, concurrent consumption with nitrates or α-
blockers may lead to life-threatening hypotension27. The remainder of the samples 
were categorised as follows: therapeutic level (13 samples), subtherapeutic level (8 
samples), and trace level (1 sample).  
 
Table 2 compiles the suspected analytes detected using the developed screening 
strategies. Samples SPC005 and SPT003 comprised of target analytes and suspected 
analytes with a total of four analytes in each sample. In contrast, sample SPT017 
contained only one suspected analyte. For example, with the suspected-target 
screening, an unidentified BPC peak at the retention time of 23.92 min from sample 
SPC005 was initially matched with two analytes, namely hydroxythiohomosildenafil 
and hydroxythiovardenafil based on the theoretical [M+H]+ precursor ion of m/z 
521.1999. As these two isomeric analytes belong to different groups of PDE5 inhibitors 
analogues, it can be clearly distinguished using the tandem MS spectra. Furthermore, 
the differences in the retention time of both analytes confirmed the presence of 
hydroxythiohomosildenafil, which was similarly detected from sample SPT003. The 
observed retention time can be tentatively assigned to hydroxythiohomosildenafil to 
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The non-targeted screening did not detect any novel PDE5 inhibitors analogues 
among the study samples. Its effectiveness and validity, however, can be 
demonstrated by the detection of aminotadalafil (a known analyte) in sample SPT003 
(Fig. 2). By using the top-down approach, an unidentified BPC peak at 17.75 min was 
integrated and extracted, revealing the observed [M+H]+ precursor ion of m/z 
391.1391. The link between the pre-determined [M+H]+ precursor ion and the product 
ions of target analytes was established using the product ion scan of the Mass Hunter 
qualitative analysis software. As a result, the tandem MS signals at the same retention 
time were specific to the common fragmentation pattern of tadalafil within ±20 ppm 
mass tolerance at m/z 135.0441 and 169.0760. Based on these findings, the “novel” 
analogue (aminotadalafil) can be flagged and narrowed down into the tadalafil group 
of analogues.  
  
Contrarily, the bottom-up approach utilised all generated [M+H]+ precursor ions during 
the chromatographic run to establish if there is any link to the product ions of target 
analytes. For sample SPT003, two tandem MS signals were detected using the 
product ion scan at different retention times for both product ions of tadalafil. These 
findings indicated the presence of two different analytes belonging to the tadalafil 
group of analogues. Indeed, one of the analytes was tadalafil based on the matching 
of the retention time at 21.12 min. Thorough investigations established the link 
between the observed [M+H]+ precursor ion of the “novel” analogue (aminotadalafil) 
at m/z 391.1391 and the product ions of tadalafil. From these findings, the chemical 
formula or structure of the “novel” analogue (aminotadalafil) can be predicted based 
on tadalafil and tentatively assigned before further structural elucidation. Fig. 3 
presents the proposed common fragmentation pattern shared by the tadalafil group of 
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analogues. Although sample SPT003 contained other analytes such as vardenafil and 
hydroxythiohomosildenafil, no interferences of the tandem MS signals were observed 
at the m/z of tadalafil product ions. 
 
The suspected analytes detected in this study, i.e. aminotadalafil and 
hydroxythiohomosildenafil, had been initially reported as adulterants in herbal remedy 
capsules28-30. The USFDA had also warned consumers on the dangers of these 
unapproved PDE5 inhibitors analogues, detected in 26 products marketed to enhance 
male sexual performance31,32. As exhibited by sample SPT003, these two analytes 
had previously detected in pairs either with33 or without34 other PDE5 inhibitors. 
 
4. CONCLUSION 
This study explored the applicability of an LC-QTOF-MS for comprehensive screening 
of PDE5 inhibitors and their analogues in herbal remedies using suspected-target and 
non-targeted strategies. The method was fully optimised and validated for 23 target 
analytes to screen 52 herbal remedy samples in capsule and tablet dosage forms. The 
screening strategies revealed 33 positive samples, identifying ten target analytes and 
detecting two suspected analytes. The target analytes were quantified from 0.03–
121.31 mg for each of the recommended dose of the samples. The DDA provides 
cleaner spectra where the observed product ions could be easily linked to their [M+H]+ 
precursor ion. The screening strategies discussed in this study would be beneficial to 
curb the widespread of adulterated herbal remedies, particularly those with PDE5 
inhibitors and their analogues. It is vital to ensure that herbal remedies do not pose 
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Table 1: Identification of target analytes and detection of suspected analytes in 
adulterated herbal remedy samples. 

















































SPC010 1. Sildenafil 35.73 - THR Unspecified 
herbs 
Malaysia 
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SPC015 1. Sildenafil 
2. Propoxyphenyl-sildenafil 
(<LOQ) 


























SPC021 1. Sildenafil 
2. Propoxyphenyl-sildenafil 
(<LOQ) 




SPC022 1. Sildenafil 
2. Propoxyphenyl-sildenafil 
(<LOQ) 



























SPC028 1. Thiodimethylsildenafil 
2. Dimethylsildenafil 
3. Thiosildenafil (<LOQ) 







SPC029 1. Sildenafil 
2. Thiodimethylsildenafil 
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SPT007 1. Sildenafil 
2. Propoxyphenyl-sildenafil 
(<LOQ) 




SPT008 1. Sildenafil 
2. Tadalafil 
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Note: TRC: trace, SUB: subtherapeutic, THE: therapeutic, SUP: supratherapeutic, 
*suspected analyte
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Fig. 1: Results summary of PDE5 inhibitors and their analogues in adulterated herbal remedy samples. (A) Identification of target 
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Fig 2: Representative base peak chromatogram (BPC); overlaid extracted ion 
chromatograms (EICs) of aminotadalafil and tadalafil; and tandem MS spectra of 
sample SPT003 demonstrating the non-targeted screening based on top-down and 
bottom-up approaches. 
BPC scan 
Product ion scan 
Any [M+H]+ -> m/z 135.0441 
 
Product ion scan 
Any [M+H]+ -> m/z 169.0760 
 
Aminotadalafil at averaged CE 
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